BPC-157 vs TB-500 vs KPV: Three Mechanisms, Compared

Last reviewed
Nov 2, 2026: every PMID and DOI was opened and checked on this date.
Reviewed by
Peak Peptides Research Team
Evidence labels
In vitroAnimalHuman
How we evaluated the evidence
We searched PubMed for each compound and its proposed pathway, read every abstract we cite (and the full text where it was open), and labelled each finding by the model that produced it. Reviews are cited for what their authors concluded, not as new data.
Disclosure
Peak Peptides sells research compounds discussed here.

In short

BPC-157 is a 15-residue gastric-juice peptide linked in cell and rat studies to nitric oxide, VEGFR2 and FAK-paxillin signalling. TB-500 is a 7-residue fragment of thymosin beta-4, the main G-actin-binding protein. KPV is a three-residue α-MSH fragment that blocks NF-κB in cells. All three rest mainly on preclinical evidence.

On this page
  1. Quick comparison
  2. BPC-157
  3. TB-500 and thymosin beta-4
  4. KPV
  5. What 2026's studies added
  6. Evidence-grade matrix
  7. FAQ
  8. References

Key takeaways

  • Three molecules, three questions. BPC-157 is studied as a signalling modulator, TB-500 through its parent protein's actin biology, KPV as an NF-κB inhibitor.[1][2][3]
  • TB-500 is not full-length thymosin beta-4. Analytical work identified it as the acetylated 17–23 fragment, Ac-LKKTETQ, and Peak's current certificate lists that same sequence.[4][5]
  • KPV depends on a transporter. In human intestinal cell lines it entered through PepT1 and lowered NF-κB activity at nanomolar concentrations.[3]
  • Human data are thin for all three. BPC-157 has three small uncontrolled reports rated very low certainty; full-length thymosin beta-4 has phase 1 safety studies; we found no human trial of KPV.[6][7]

How do BPC-157, TB-500 and KPV compare at a glance?

In vitroAnimalHuman

They differ in size, origin and target. BPC-157 vs TB-500 is the pairing most often searched; KPV adds a third, unrelated pathway.

BPC-157 vs TB-500 vs KPV (as of Nov 2, 2026)
FeatureBPC-157TB-500KPV
OriginPartial sequence of "body protection compound" from human gastric juice[8]Synthetic, N-acetylated 17–23 fragment of thymosin beta-4 (Tβ4)[4][9]C-terminal tripeptide of α-MSH, residues 11–13[10]
Sequence and sizeGly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val; 15 residues, MW 1419[11]Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln; 7 residues[4][5]Lys-Pro-Val; 3 residues[3]
Proposed mechanismInteraction with nitric oxide (NO) signalling; VEGFR2-Akt-eNOS activation; FAK-paxillin phosphorylation[12][13][8]Parent protein Tβ4 binds G-actin 1:1; the 17–22 motif is part of that binding site[14][15]Inhibits NF-κB and MAP kinase signalling after PepT1-mediated uptake[3]
Model systems studiedRat gastric and blood-pressure models, rat hind-limb ischaemia, chick membrane assay, endothelial cells, rat tendon fibroblasts[12][13][8]Tβ4: platelets, neutrophils, purified actin. TB-500 as supplied: one 2026 rat tendon study[14][16][17]Human intestinal epithelial and T-cell lines; mouse colitis models[3][10]
Human data statusThree small uncontrolled studies (n = 30 in total); certainty very low[6]None found for the fragment. Full-length Tβ4: phase 1 safety studies in healthy volunteers[7][18]No human trial found

MW: molecular weight in daltons. VEGFR2: vascular endothelial growth factor receptor 2. FAK: focal adhesion kinase. "KPV: no human trial found" reflects a PubMed and ClinicalTrials.gov search on Nov 2, 2026.

What is BPC-157, and which signalling pathways are proposed?

In vitroAnimal

BPC-157 is a stable 15-amino-acid peptide whose proposed mechanisms come almost entirely from rat and cell studies. Three pathways recur: nitric oxide, VEGFR2 and FAK-paxillin.

Its name comes from "body protection compound," a larger protein its developers isolated from human gastric juice; BPC-157 is a 15-residue partial sequence of it.[8] Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val.[11] Our evidence overview, BPC-157 Canada research evidence, covers the wider literature; here we focus on mechanism.

Nitric oxide (animal, tissue homogenate)

Nitric oxide (NO) is a short-lived signalling gas made by NO synthase enzymes from L-arginine. In a 1997 rat study, L-NAME (an NO-synthase blocker) fully abolished the gastric effect of L-arginine but only weakened that of BPC-157. In rat gastric-mucosa homogenates, BPC-157 generated NO to a degree comparable with L-arginine, and L-NAME could not block it even at a tenfold excess. The authors concluded that BPC-157 interacts with the NO system "in a specific way" that differs from L-arginine.[12]

VEGFR2 and angiogenesis (in vitro and animal)

Angiogenesis is the growth of new blood vessels from existing ones, and VEGFR2 is the receptor that carries most of its growth-factor signal. Hsieh and colleagues found that BPC-157 increased vessel density in the chick chorioallantoic membrane assay and in endothelial tube-formation assays. In rats with hind-limb ischaemia (cut-off blood supply), it increased vessel number and VEGFR2 expression in muscle. In human vascular endothelial cells it raised VEGFR2 mRNA and protein but not VEGF-A, promoted VEGFR2 internalisation and activated the VEGFR2-Akt-eNOS pathway. Dynasore, an inhibitor of endocytosis, blocked those effects.[13]

FAK-paxillin (in vitro, rat cells)

Focal adhesion kinase (FAK) and its partner paxillin are proteins at the points where cells grip their surroundings; phosphorylating them is a signal for cells to spread and move. In fibroblasts from rat Achilles tendon, BPC-157 did not change proliferation but increased survival under hydrogen-peroxide stress, migration and spreading. It induced F-actin formation and increased phosphorylation of FAK and paxillin in a concentration-dependent manner, with total protein levels unchanged.[8]

A 2025 review describes the same overlapping VEGFR2, Akt-eNOS and ERK1/2 picture across animal models, and calls human data "extremely limited."[1]

What is TB-500, and how does it relate to thymosin beta-4?

In vitroHuman (full-length Tβ4 only)

TB-500 is a short synthetic fragment of thymosin beta-4, not the whole protein. Most of the mechanism data people associate with it, chiefly G-actin sequestration, were measured on full-length thymosin beta-4.

The parent protein: thymosin beta-4

Actin is the protein that forms the cell's internal scaffolding. It exists as single units (G-actin) and as filaments (F-actin). Thymosin beta-4 (Tβ4) is a small, acidic 5-kDa peptide. In 1991 Safer and colleagues showed that Fx, the peptide holding most unpolymerised actin in resting human platelets, is identical to Tβ4. It forms a 1:1 complex with actin monomers and inhibits their polymerisation; this is called G-actin sequestration.[14] In resting human neutrophils, Tβ4 reaches about 149 µM in the cytoplasm and appears to be the major G-actin-sequestering protein.[16] Reviews call β-thymosins "actin buffers" that hold monomers in reserve.[2]

The picture has nuances. Above about 20 µM, Tβ4 also interacts with F-actin, so it is "not a simple passive actin-sequestering agent."[19] Its N-terminus is acetylated during biosynthesis, and the enzyme prolyl oligopeptidase can cut a different fragment, Ac-SDKP, from it.[20] Our TB-500 and thymosin beta-4 guide covers the parent protein in more depth.

The fragment: Ac-LKKTETQ

Analytical chemists at Ghent identified the active ingredient of a TB-500 product as the N-terminally acetylated 17–23 fragment of human Tβ4, Ac-LKKTETQ, using high-resolution mass spectrometry, then synthesised it as a reference.[4] A separate analytical study of a veterinary TB-500 preparation reached the same identity, describing the acetylation as artificial.[9] The certificate of analysis for Peak's current TB-500 lot lists Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln, molecular weight 889.01 g/mol.[5]

Mutational mapping places Tβ4's actin-binding site in two parts: an N-terminal helix (residues 1–16) and a hexapeptide motif (residues 17–22), with lysine 18 in the motif important for contact.[15] TB-500 contains that motif but not the N-terminal helix. How much of the parent's actin-sequestering behaviour a seven-residue fragment retains is not established by the sources we reviewed.

Human data

We found no human study of the Ac-LKKTETQ fragment. Full-length synthetic Tβ4 was given intravenously to healthy volunteers in a randomised, placebo-controlled phase 1 study (four cohorts of 10); adverse events were infrequent and mild or moderate.[7] A phase 1 study of recombinant human Tβ4 in 84 healthy volunteers reported similar tolerability.[18] Neither tested TB-500, and neither measured efficacy.

What is KPV, and what do the NF-κB and PepT1 findings show?

In vitroAnimal

KPV is lysine-proline-valine, the last three residues of α-MSH. In cell and mouse studies, it enters cells through the PepT1 transporter and dampens NF-κB signalling.

α-MSH (alpha-melanocyte-stimulating hormone) is a 13-residue peptide that, beyond pigmentation, modulates immune cells, largely through the melanocortin-1 receptor (MC1R) and by inhibiting the transcription factor NF-κB, a master switch for inflammatory genes. Its C-terminal tripeptide, α-MSH(11–13) or KPV, was also able to bind MC1R and to modulate antigen-presenting cells, and inhibited contact hypersensitivity in mice.[21]

NF-κB and PepT1 (in vitro and animal)

PepT1 is a transporter that moves di- and tripeptides into cells. It is normally expressed in the small intestine and is induced in the colon during inflammatory bowel disease. In human intestinal epithelial cell lines (Caco2-BBE and HT29-Cl.19A) and Jurkat T cells, nanomolar KPV inhibited NF-κB and MAP kinase activation and reduced pro-inflammatory cytokine secretion. Uptake studies showed that KPV acts via PepT1. KPV given in drinking water reduced the incidence of chemically induced colitis in two mouse models.[3]

Two further mouse studies refine the mechanism. In colitis models, KPV reduced inflammatory infiltrates and myeloperoxidase activity, and remained active in mice with non-functional MC1R. The authors concluded its effects are "at least partially independent" of MC1R.[10] In a model of colitis-associated cancer, KPV reduced tumour development in normal mice but had no effect in PepT1-knockout mice. That points to PepT1 as necessary for its activity there.[22]

Sidebar: where does GHK-Cu fit?

GHK-Cu is often compared with BPC-157, but it is a different kind of molecule: glycyl-L-histidyl-L-lysine, a naturally occurring human tripeptide studied as a copper complex. Reviews link it to collagen and glycosaminoglycan synthesis, fibroblast function and broad gene-expression changes. That is a different proposed mechanism from BPC-157's NO, VEGFR2 and FAK-paxillin findings.[23] A 2026 scoping review that included both found human data limited for each.[24] See our GHK-Cu research overview.

What did 2026's studies add?

AnimalReviews of human and animal data

One small rat study compared BPC-157 and TB-500 head to head, and two reviews weighed the field. None changes the overall grade: mostly animal evidence, sparse human data.

Rat Achilles tendon model, BPC-157 vs TB-500 (animal)

Biçer and colleagues randomised 32 male Sprague-Dawley rats with surgically cut and repaired Achilles tendons to four groups of eight: control, BPC-157, TB-500, or both. Compounds were given daily by intraperitoneal injection for four weeks.[17] At four weeks:

  • Load to failure. Both peptide groups had higher maximum load to failure than controls, but only TB-500 reached statistical significance. The full text shows four tendons per group in this test.[17]
  • Histology. Total Bonar scores, a tendon-histology scale on which lower is better, were significantly lower with TB-500 (p = 0.016). Total Movin scores were lower with TB-500 (p = 0.017) and the combination (p = 0.040). BPC-157 scores were numerically lower but not significant.[17]
  • Collagen. Type I collagen expression did not differ between groups; type III differed significantly.[17]
  • Combination. Giving both compounds "did not confer additional benefits" over either alone.[17]

The authors call the work exploratory, and the samples are small. The paper describes TB-500 as "synthetic thymosin beta-4" without giving its sequence, so it is not certain which molecule was tested. Our BPC-157 and TB-500 research guide covers earlier work on the pair.

AJSM scoping review of six peptides

Tewari and colleagues (UCLA) screened PubMed for BPC-157, thymosin beta-4/TB-500, CJC-1295, MK-677, ipamorelin and GHK-Cu in musculoskeletal tissue. Of the publications they identified, 67% used animal models, most often rats. Human studies were "limited to a handful of investigations, most lacking robust controls or rigorous study designs." The authors concluded that claimed musculoskeletal benefits "remain unsubstantiated by current human trials."[24]

Curr Pain Headache Rep narrative review

A Brigham and Women's Hospital group reviewed regenerative peptides, including BPC-157, thymosin beta-4 and TB-500 (listed as separate entries), GHK-Cu, collagen peptides and cibinetide. They concluded that human clinical evidence is limited.[25]

How strong is the evidence for each compound?

In vitroAnimalHuman

Mechanistic depth and human evidence run in opposite directions. Tβ4's actin biology is the best characterised at the molecular level; BPC-157 has the most animal work; none of the three has a controlled human efficacy trial.

Evidence by model, with PMIDs (as of Nov 2, 2026)
CompoundIn vitroAnimalHuman
BPC-157VEGFR2-Akt-eNOS in human endothelial cells (PMID 27847966)[13]; FAK-paxillin in rat tendon fibroblasts (PMID 21030672)[8]; NO generation in gastric tissue homogenate (PMID 9298922)[12]Rat NO-system studies (PMID 9298922)[12]; rat hind-limb ischaemia (PMID 27847966)[13]; rat Achilles model, 2026 (PMID 42542926)[17]Three uncontrolled studies, n = 30, very low certainty (PMID 42885452)[6]; primary reports PMIDs 34324435, 39325560, 40131143[26][27][28]
TB-500 (Ac-LKKTETQ)Parent Tβ4: 1:1 G-actin binding (PMID 1999398)[14]; binding-site map (PMID 8617195)[15]; F-actin interaction (PMID 8621582)[19]. Fragment identity (PMIDs 22962027, 23084823)[4][9]Rat Achilles model, 2026; sequence not reported (PMID 42542926)[17]None found for the fragment. Full-length Tβ4 phase 1 safety (PMIDs 20536472, 34346165)[7][18]
KPVNF-κB and MAPK inhibition via PepT1 in human intestinal and T-cell lines (PMID 18061177)[3]; MC1R binding on antigen-presenting cells (PMID 12851308)[21]Mouse colitis (PMIDs 18061177, 18092346)[3][10]; colitis-associated cancer, PepT1-dependent (PMID 27458604)[22]No trial found

"Human" means studies in people, not human cell lines; work on human cells is listed under in vitro. A cell or rat result shows that a pathway can be engaged in that model, not that the same happens in people.

Frequently asked questions

What is the difference between BPC-157 and TB-500?

They are unrelated molecules. BPC-157 is a 15-residue peptide from a gastric-juice protein, studied for nitric oxide, VEGFR2 and FAK-paxillin signalling. TB-500 is a seven-residue acetylated fragment of thymosin beta-4; the G-actin-binding mechanism usually attributed to it was measured on the full-length parent protein.[8][13][4][14]

What are BPC-157 and TB-500 used for in research?

In published research they serve as tools in cell and animal models. BPC-157 has been studied in gastric, vascular and tendon-fibroblast systems; thymosin beta-4 in actin and cell-motility biology; and TB-500 in analytical chemistry and one 2026 rat tendon model. Neither has controlled human efficacy data.[12][13][8][4][17][6]

How does KPV differ from BPC-157 and TB-500?

KPV is only three residues long (Lys-Pro-Val), derived from α-MSH. Its best-documented mechanism is anti-inflammatory: after entering cells through the PepT1 transporter, it inhibits NF-κB signalling. BPC-157 and TB-500 are studied for vascular, adhesion and actin-related pathways instead.[3][10]

Is TB-500 the same as thymosin beta-4?

No. Thymosin beta-4 is a 5-kDa protein. TB-500 has been identified as Ac-LKKTETQ, its acetylated 17–23 fragment, which contains part of the protein's actin-binding site but not all of it. Findings for full-length thymosin beta-4 should not be assumed to apply to the fragment.[14][4][15]

What did the 2026 rat study comparing BPC-157 and TB-500 find?

In 32 rats with repaired Achilles tendons, TB-500 was associated with significantly higher load to failure and better histology scores than controls at four weeks. BPC-157's differences were not significant, and giving both added nothing over either alone. The authors describe the study as exploratory.[17]

How does BPC-157 compare with GHK-Cu?

GHK-Cu is a copper-binding human tripeptide (glycyl-L-histidyl-L-lysine), studied for collagen synthesis, fibroblast function and gene-expression changes. BPC-157 is a 15-residue peptide studied for NO, VEGFR2 and FAK-paxillin signalling. A 2026 scoping review that covered both found limited human data for each.[23][24]

BPC-157 research evidenceThe wider BPC-157 literature, study by study. TB-500 and thymosin beta-4The parent protein in more depth. BPC-157 and TB-500 research guideEarlier work on the two compounds together. GHK-Cu research overviewThe copper tripeptide, for comparison.

Bottom line

BPC-157, TB-500 and KPV share little beyond being short peptides. BPC-157's proposed mechanisms come from rat and cell studies of NO, VEGFR2 and FAK-paxillin. TB-500 is a fragment whose actin biology is inferred from its parent protein. KPV is a PepT1-dependent NF-κB inhibitor in cell and mouse models. For all three, the human evidence remains thin.

Continue your research

Explore the compounds in this article

All three peptides compared here are available to researchers in Canada as reference materials, each with its batch certificate of analysis.

Research compoundBPC-157 10 mg15 residues, GEPPPGKPADDAGLV. Current batch and COA on the product page. Research compoundTB-500 10 mgAc-LKKTETQ, the acetylated Tβ4 17–23 fragment. Current batch and COA on the product page. Research compoundKPV 10 mgLys-Pro-Val, α-MSH 11–13. Current batch and COA on the product page. Full catalogueAll research compoundsBrowse every compound, each with its batch Certificate of Analysis.
  • Every batch third-party tested, >98% purity, COA published, plus in-house retesting of sample vials per batch.
  • Ships from Toronto, discreet and tracked. Same day if placed and paid before 12 PM Toronto time; 1–3 business days within Toronto, 3–5 business days Canada-wide.
  • Payment by Interac e-Transfer.
  • For research use only. Not for human consumption.

Compounds in this article

TB 500 10mg →BPC-157 10mg →

Third-party tested · COA with every batch · shipped from Canada · for research use only

Get the Peak Peptides Research Letter

One email a week: the newest peptide studies, what they found, and the regulatory news that matters in Canada. Free, and you can unsubscribe anytime.

Subscribe free

References

  1. McGuire FP, Martinez R, Lenz A, et al. Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Curr Rev Musculoskelet Med. 2025;18(12):611-619. DOI 10.1007/s12178-025-09990-7PMID 40789979PMC12446177 ↩
  2. Huff T, Müller CS, Otto AM, et al. β-Thymosins, small acidic peptides with multiple functions. Int J Biochem Cell Biol. 2001;33(3):205-220. DOI 10.1016/s1357-2725(00)00087-xPMID 11311852 ↩
  3. Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. DOI 10.1053/j.gastro.2007.10.026PMID 18061177PMC2431115 ↩
  4. Esposito S, Deventer K, Goeman J, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-738. DOI 10.1002/dta.1402PMID 22962027 ↩
  5. Peak Peptides. Certificate of Analysis: TB 500, 10 mg, batch/lot 019762 (test date March 2026). COA PDF Peak's own batch document, cited for the sequence of the material sold. ↩
  6. Poolton JT, Minett J, Kazmi A. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthop Belg. 2026;92(3). DOI 10.52628/92.3.15837PMID 42885452 ↩
  7. Ruff D, Crockford D, Girardi G, Zhang Y. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010;1194:223-229. DOI 10.1111/j.1749-6632.2010.05474.xPMID 20536472 ↩
  8. Chang CH, Tsai WC, Lin MS, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780. DOI 10.1152/japplphysiol.00945.2010PMID 21030672 ↩
  9. Ho EN, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012;1265:57-69. DOI 10.1016/j.chroma.2012.09.043PMID 23084823 ↩
  10. Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-331. DOI 10.1002/ibd.20334PMID 18092346 ↩
  11. Jelovac N, Sikiric P, Rucman R, et al. Pentadecapeptide BPC 157 attenuates disturbances induced by neuroleptics: the effect on catalepsy and gastric ulcers in mice and rats. Eur J Pharmacol. 1999;379(1):19-31. DOI 10.1016/s0014-2999(99)00486-0PMID 10499368 ↩
  12. Sikirić P, Seiwerth S, Grabarević Z, et al. The influence of a novel pentadecapeptide, BPC 157, on N(G)-nitro-L-arginine methylester and L-arginine effects on stomach mucosa integrity and blood pressure. Eur J Pharmacol. 1997;332(1):23-33. DOI 10.1016/s0014-2999(97)01033-9PMID 9298922 ↩
  13. Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. DOI 10.1007/s00109-016-1488-yPMID 27847966 ↩
  14. Safer D, Elzinga M, Nachmias VT. Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable. J Biol Chem. 1991;266(7):4029-4032. PMID 1999398 ↩
  15. Van Troys M, Dewitte D, Goethals M, et al. The actin binding site of thymosin beta 4 mapped by mutational analysis. EMBO J. 1996;15(2):201-210. PMID 8617195PMC449934 ↩
  16. Cassimeris L, Safer D, Nachmias VT, Zigmond SH. Thymosin beta 4 sequesters the majority of G-actin in resting human polymorphonuclear leukocytes. J Cell Biol. 1992;119(5):1261-1270. DOI 10.1083/jcb.119.5.1261PMID 1447300 ↩
  17. Biçer O, Adanir O, Güleryüz Y, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: a histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822-837. Published July 23, 2026. DOI 10.52312/jdrs.2026.2951PMID 42542926 ↩
  18. Wang X, Liu L, Qi L, et al. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers. J Cell Mol Med. 2021;25(17):8222-8228. DOI 10.1111/jcmm.16693PMID 34346165PMC8419156 ↩
  19. Carlier MF, Didry D, Erk I, et al. Tβ4 is not a simple G-actin sequestering protein and interacts with F-actin at high concentration. J Biol Chem. 1996;271(16):9231-9239. DOI 10.1074/jbc.271.16.9231PMID 8621582 ↩
  20. Hannappel E. Thymosin β4 and its posttranslational modifications. Ann N Y Acad Sci. 2010;1194:27-35. DOI 10.1111/j.1749-6632.2010.05485.xPMID 20536447 ↩
  21. Luger TA, Scholzen TE, Brzoska T, Böhm M. New insights into the functions of α-MSH and related peptides in the immune system. Ann N Y Acad Sci. 2003;994:133-140. DOI 10.1111/j.1749-6632.2003.tb03172.xPMID 12851308 ↩
  22. Viennois E, Ingersoll SA, Ayyadurai S, et al. Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model. Cell Mol Gastroenterol Hepatol. 2016;2(3):340-357. DOI 10.1016/j.jcmgh.2016.01.006PMID 27458604PMC4957955 ↩
  23. Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987. DOI 10.3390/ijms19071987PMID 29986520PMC6073405 ↩
  24. Tewari K, Liu TP, Im C, et al. Peptide supplements and their therapeutic applications in sports medicine. Am J Sports Med. Published online August 11, 2026. DOI 10.1177/03635465261464420PMID 42578445 ↩
  25. Luansritisakul C, Chiang MC, Burns SL, Fonseca ACG. Peptides in regenerative medicine: a comprehensive review of clinical applications in tissue repair and chronic pain management. Curr Pain Headache Rep. 2026;30(1):109. DOI 10.1007/s11916-026-01542-zPMID 42635865 ↩
  26. Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021;27(4):8-13. PMID 34324435 Retrospective, uncontrolled. ↩
  27. Lee E, Walker C, Ayadi B. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. Altern Ther Health Med. 2024;30(10):12-17. PMID 39325560 Uncontrolled pilot. ↩
  28. Lee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med. 2025;31(5):20-24. PMID 40131143 Two participants. ↩

Every batch third-party tested, >98% purity, COA published, plus in-house retesting of sample vials per batch. Ships from Toronto, discreet and tracked. Orders placed and paid before 12 PM Toronto time ship the same day; 1–3 business days within Toronto, 3–5 business days Canada-wide. Payment by Interac e-Transfer.

For laboratory research use only. Not for human or veterinary use. This article summarises published research for educational purposes. It is not medical advice, not instructions for use and not a claim of benefit. Nothing here is intended to diagnose, treat, cure or prevent any disease.

All products are sold for laboratory research use only. Not for human consumption.